China SXT Pharmaceuticals, Inc. (SXTC): Cost of Revenue
$889.4K
Year ended 2026-03-31
-16.8%
3-year compound annual growth
-14.4%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $889.4K | -35.2% | 2026-07-01, From 2025-04-01 |
| 2025-03-31 | $1.37M | -0.1% | 2026-07-01, From 2024-04-01 |
| 2024-03-31 | $1.37M | -11.1% | 2026-07-01, From 2023-04-01 |
| 2023-03-31 | $1.55M | +14.4% | 2025-07-31, From 2022-04-01 |
| 2022-03-31 | $1.35M | -30.3% | 2024-08-13, From 2021-04-01 |
| 2021-03-31 | $1.94M | -21.2% | 2023-07-31, From 2020-04-01 |
| 2020-03-31 | $2.46M | +2.4% | 2023-05-19, From 2019-04-01 |
| 2019-03-31 | $2.40M | -33.6% | 2021-08-13, From 2018-04-01 |
| 2018-03-31 | $3.62M | +40.8% | 2020-07-31, From 2017-04-01 |
| 2017-03-31 | $2.57M | n/a | 2019-08-15, From 2016-04-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| China SXT Pharmaceuticals, Inc. (SXTC) | 2026-03-31 | $889.4K | -35.2% |
| Bespoke Extracts, Inc. (BSPK) | 2024-12-31 | $664.5K | +50.2% |
| Longeveron Inc. (LGVN) | 2025-12-31 | $396.0K | -22.0% |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $295.8K | n/a |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $652.0K | +6.5% |
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | 2025-12-31 | $781.7K | +103.2% |
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | $3.45M | -8.2% |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | $505.0K | n/a |
| Onconetix, Inc. (ONCO) | 2025-12-31 | $182.5K | -87.6% |
Compare SXTC, BSPK, LGVN, DARE side by side · Screen every company in Pharmaceutical Preparations ↗